Pfizer asks for formal U.S. approval of oral COVID treatment Paxlovid
Pfizer Inc said on Thursday it is seeking full U.S. approval for its oral COVID-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorization (EUA). Pfizer said it submitted a New Drug Application for Paxlovid to the Food and Drug Administration for the treatment of COVID-19 in vaccinated and unvaccinated people at high risk of progression to severe illness.
Reuters - June 30, 2022View the full story here: https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-asks-formal-us-approval-oral-covid-treatment-paxlovid-2022-06-30/